Genmab A/S (NASDAQ:GMAB) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Genmab A/S (NASDAQ:GMAB) from a hold rating to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Other analysts have also issued research reports about the company. Truist Financial upped their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a report on Saturday, September 27th. HC Wainwright upped their target price on Genmab A/S from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Wall Street Zen upgraded Genmab A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $33.56 on Thursday. The company has a market cap of $21.53 billion, a PE ratio of 16.86, a PEG ratio of 1.82 and a beta of 0.98. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $33.61. The stock has a 50-day simple moving average of $25.84 and a 200 day simple moving average of $22.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds have recently made changes to their positions in the business. Headlands Technologies LLC lifted its position in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after buying an additional 1,464 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the last quarter. CWM LLC lifted its position in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after buying an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after purchasing an additional 1,070 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new stake in Genmab A/S in the 2nd quarter valued at $44,000. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.